🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2024-516446-18-00
Authorised Phase I

Study to look at the safety, tolerability, and how the body processes the study medicine WAL0623 after single or repeated doses, with or without food, in healthy volunteers

2024-516446-18-00 · tracked via the Priya Life Science EU tracker
Sponsor
Walden Biosciences Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Male Urogenital Diseases
Decision date
27/01/2026
Enrollment target
84
Sites
Italy

Condition studied

Glomerular kidney diseases with proteinuria

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-516446-18-00 on CTIS ↗ ← All trials in the EU